Syndax Pharmaceuticals Inc
NASDAQ:SNDX
| Market Cap (Intraday) | 1.27B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $16.00 |
| 50-Day MA | $12.75 |
| 200-Day MA | $12.84 |
Syndax Pharmaceuticals Inc Stock, NASDAQ:SNDX
730 Third Avenue, floor 9, New York, New York 10017
United States of America
Phone: +1.781.419.1400
Number of Employees: 270
Description
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.